目次

1. Executive Summary
1.1.Regional Market Share
1.2. Business Trends
1.3. Dry Age-Related Macular Degeneration Market: COVID-19 Outbreak
1.4.Regional Trends
1.5. Segmentation Snapshot

2. Research Methodology
2.1. Research Objective
2.2.Research Approach
2.3.Data Sourcing and Methodology
2.4. Primary Research
2.5. Secondary Research
2.5.1.Paid Sources
2.5.2. Public Sources
2.6.Market Size Estimation and Data Triangulation

3. Market Characteristics
3.1. Market Definition
3.2.Dry Age-Related Macular Degeneration Market: COVID-19 Impact
3.3.Key Segmentations
3.4. Key Developments
3.5. Allied Industry Data

4. Dry Age-Related Macular Degeneration Market - Industry Insights
4.1.Industry Segmentation
4.2. COVID-19 overview on world economy
4.3. Industry ecosystem Channel analysis
4.4. Innovation & Sustainability

5. Macroeconomic Indicators

6. Recent Developments
7.Market Dynamics
7.1. Introduction
7.2.Growth Drivers
7.3.Market Opportunities
7.4. Market Restraints
7.5.Market Trends

8. Market Analysis
8.1. Porters Five Forces
8.2. PEST Analysis
8.2.1. Political
8.2.2.Economic
8.2.3.Social
8.2.4.Technological

9. Dry Age-Related Macular Degeneration Market
9.1. Overview
9.2.Historical Analysis (2016-2021)
9.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast

10. Dry Age-Related Macular Degeneration Market Size & Forecast 2022A-2032F
10.1.Overview
10.2. Key Findings
10.3. Market Segmentation
10.3.1. By Stages
10.3.1.1.Early AMD
10.3.1.1.1.By Value (USD Million) 2022-2032F
10.3.1.1.2. Market Share (%) 2022-2032F
10.3.1.1.3. Y-o-Y Growth (%) 2022-2032F
10.3.1.2. Intermediate AMD
10.3.1.2.1. By Value (USD Million) 2022-2032F
10.3.1.2.2.Market Share (%) 2022-2032F
10.3.1.2.3.Y-o-Y Growth (%) 2022-2032F
10.3.1.3. Late AMD
10.3.1.3.1. By Value (USD Million) 2022-2032F
10.3.1.3.2.Market Share (%) 2022-2032F
10.3.1.3.3.Y-o-Y Growth (%) 2022-2032F
10.3.2.By Age Group
10.3.2.1. Above 75 Years
10.3.2.1.1. By Value (USD Million) 2022-2032F
10.3.2.1.2.Market Share (%) 2022-2032F
10.3.2.1.3.Y-o-Y Growth (%) 2022-2032F
10.3.2.2.Above 60 Years
10.3.2.2.1.By Value (USD Million) 2022-2032F
10.3.2.2.2. Market Share (%) 2022-2032F
10.3.2.2.3. Y-o-Y Growth (%) 2022-2032F
10.3.2.3.Above 40 Years
10.3.2.3.1.By Value (USD Million) 2022-2032F
10.3.2.3.2. Market Share (%) 2022-2032F
10.3.2.3.3.Y-o-Y Growth (%) 2022-2032F
10.3.3.By Diagnosis and Treatment
10.3.3.1. Treatment
10.3.3.1.1. By Value (USD Million) 2022-2032F
10.3.3.1.2.Market Share (%) 2022-2032F
10.3.3.1.3.Y-o-Y Growth (%) 2022-2032F
10.3.3.2.Diagnosis
10.3.3.2.1.By Value (USD Million) 2022-2032F
10.3.3.2.2. Market Share (%) 2022-2032F
10.3.3.2.3.Y-o-Y Growth (%) 2022-2032F
10.3.4.By Route of Administration
10.3.4.1. Oral
10.3.4.1.1.By Value (USD Million) 2022-2032F
10.3.4.1.2. Market Share (%) 2022-2032F
10.3.4.1.3. Y-o-Y Growth (%) 2022-2032F
10.3.4.2.Injectables
10.3.4.2.1. By Value (USD Million) 2022-2032F
10.3.4.2.2.Market Share (%) 2022-2032F
10.3.4.2.3.Y-o-Y Growth (%) 2022-2032F
10.3.5.By End User
10.3.5.1. Hospitals & Clinics
10.3.5.1.1. By Value (USD Million) 2022-2032F
10.3.5.1.2.Market Share (%) 2022-2032F
10.3.5.1.3. Y-o-Y Growth (%) 2022-2032F
10.3.5.2.Diagnostic Centers
10.3.5.2.1.By Value (USD Million) 2022-2032F
10.3.5.2.2.Market Share (%) 2022-2032F
10.3.5.2.3.Y-o-Y Growth (%) 2022-2032F
10.3.5.3.Academic Research Institutes
10.3.5.3.1. By Value (USD Million) 2022-2032F
10.3.5.3.2.Market Share (%) 2022-2032F
10.3.5.3.3.Y-o-Y Growth (%) 2022-2032F
10.3.5.4.Others
10.3.5.4.1. By Value (USD Million) 2022-2032F
10.3.5.4.2.Market Share (%) 2022-2032F
10.3.5.4.3.Y-o-Y Growth (%) 2022-2032F
11.North America Dry Age-Related Macular Degeneration Market Size & Forecast 2022A-2032F
11.1.Overview
11.2. Key Findings
11.3. Market Segmentation
11.3.1.By Stages
11.3.2. By Age Group
11.3.3. By Diagnosis and Treatment
11.3.4. By Route of Administration
11.3.5. By End User
11.4.Country
11.4.1. United States
11.4.2.Canada

12. Europe Dry Age-Related Macular Degeneration Market Size & Forecast 2022A-2032F
12.1. Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1. By Stages
12.3.2.By Age Group
12.3.3.By Diagnosis and Treatment
12.3.4.By Route of Administration
12.3.5.By End User
12.4. Country
12.4.1.Germany
12.4.2. United Kingdom
12.4.3. France
12.4.4. Italy
12.4.5. Spain
12.4.6. Russia
12.4.7. Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)

13. Asia Dry Age-Related Macular Degeneration Market Size & Forecast 2022A-2032F
13.1. Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1. By Stages
13.3.2.By Age Group
13.3.3.By Diagnosis and Treatment
13.3.4.By Route of Administration
13.3.5.By End User
13.4. Country
13.4.1.India
13.4.2. China
13.4.3. South Korea
13.4.4. Japan
13.4.5. Rest of APAC

14. Middle East and Africa Dry Age-Related Macular Degeneration Market Size & Forecast 2022A-2032F
14.1.Overview
14.2. Key Findings
14.3. Market Segmentation
14.3.1. By Stages
14.3.2.By Age Group
14.3.3.By Diagnosis and Treatment
14.3.4. By Route of Administration
14.3.5.By End User
14.4. Country
14.4.1.Israel
14.4.2. GCC
14.4.3. North Africa
14.4.4. South Africa
14.4.5. Rest of Middle East and Africa

15. Latin America Dry Age-Related Macular Degeneration Market Size & Forecast 2022A-2032F
15.1.Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1. By Stages
15.3.2.By Age Group
15.3.3.By Diagnosis and Treatment
15.3.4.By Route of Administration
15.3.5.By End User
15.4. Country
15.4.1.Mexico
15.4.2. Brazil
15.4.3. Rest of Latin America

16. Competitive Landscape
16.1. Company market share, 2021
16.2. Key player overview
16.3. Key stakeholders

17. Company Profiles
17.1.Roche
17.1.1.Company Overview
17.1.2. Financial Overview
17.1.3. Key Product; Analysis
17.1.4.Company Assessment
17.1.4.1.Product Portfolio
17.1.4.2. Key Clients
17.1.4.3. Market Share
17.1.4.4. Recent News & Development (Last 3 Yrs.)
17.1.4.5. Executive Team
17.2. Bausch Health
17.3. Allergan plc
17.4. Santen Pharmaceuticals Inc.
17.5. Ocumension Therapeutics Co. Ltd
17.6. Apellis Pharmaceuticals
17.7. Gyroscope Therapeutics
17.8. Iveric Bio
17.9. CellCure Neurosciences
17.10. Stealth Biotherapeutics Corp.
17.11.Eyestem Research Pvt Ltd
17.12. Belite Bio Inc.
17.13. Kubota Vision Inc.
17.14. Evergreen Therapeutics
17.15. Alkeus Pharmaceuticals
17.16. Other Prominent Players

18. Appendix

19. Consultant Recommendation